Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transfusion safety: what has been done; what is still needed?

MLO: medical laboratory observer·2005

Same author

The new WHO nomenclature: introduction and myeloid neoplasms.

Clinical laboratory science : journal of the American Society for Medical Technology·2003

Same author

The new WHO nomenclature: lymphoid neoplasms.

Clinical laboratory science : journal of the American Society for Medical Technology·2003

Same author

Use of blood products and factor concentrates for coagulation therapy.

Clinical laboratory science : journal of the American Society for Medical Technology·2003

Search research articles

Related Experiment Videos

Hitting the target with antithrombotic therapy.

Margaret G Fritsma¹, Bernadette F Rodak

¹School of Health Professions at the University of Alabama-Birmingham, USA.

MLO: Medical Laboratory Observer

|April 10, 2008

Summary

This summary is machine-generated.

Effective thrombus treatment and prevention involve various drugs, including oral warfarin. Many anticoagulant therapies necessitate laboratory monitoring to ensure efficacy and detect adverse events like bleeding or heparin-induced thrombocytopenia.

Related Experiment Videos

Area of Science:

Pharmacology
Hematology
Clinical Medicine

Background:

Thrombus formation and embolism pose significant health risks.
Current treatments include anticoagulants administered intravenously, subcutaneously, or orally (e.g., warfarin).

Purpose of the Study:

To review the landscape of anticoagulant therapies.
To highlight the critical role of laboratory monitoring in managing these treatments.

Main Methods:

Literature review of anticoagulant drugs and monitoring protocols.
Analysis of common adverse events associated with antithrombotic therapies.

Main Results:

A range of anticoagulant medications are available for clinical use.
Laboratory monitoring is essential for assessing treatment efficacy.
Monitoring is crucial for identifying serious complications such as bleeding and heparin-induced thrombocytopenia.

Conclusions:

Optimizing thrombus treatment requires careful selection of antithrombotic agents.
Regular laboratory assessment is indispensable for safe and effective anticoagulation therapy.